Literature DB >> 1519168

Etiology and management of respiratory complications after repair of esophageal atresia with tracheoesophageal fistula.

R E Delius1, M J Wheatley, A G Coran.   

Abstract

This article reviews the cause and management of respiratory symptoms after repair of esophageal atresia with tracheoesophageal fistula (TEF). Postoperative respiratory symptoms developed in 31 (46%) of 68 patients and included apnea and bradycardia, respiratory arrest, aspiration, and recurrent pneumonia. The respiratory symptoms were initially attributed to gastroesophageal reflux (GER) in 20 patients (64%), tracheomalacia in 4 patients (13%), recurrent TEF in 4 patients (13%), and anastomotic stricture in 3 patients (10%). Three patients with GER and the three patients with a stricture were initially managed nonoperatively. The remaining 25 patients underwent surgical correction of the underlying cause of the respiratory symptoms. Despite aggressive management of this problem, 14 (45%) of these 31 patients had persistent or recurrent respiratory symptoms. Although GER is the most common cause of respiratory complications in patients who have undergone prior TEF repair, other factors are often responsible for these symptoms and should not be overlooked.

Entities:  

Mesh:

Year:  1992        PMID: 1519168

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  3 in total

1.  Ventricular septal defect closure in a patient with VACTERL syndrome: anticipating sequelae in a rare genetic disorder.

Authors:  Ali Can Hatemi; Mete Gursoy; Kadir Ceviker; Aybala Tongut; Gurkan Cetin; Serdar Celebi; Erhan Kansiz
Journal:  Tex Heart Inst J       Date:  2008

2.  A case of VACTERL and non-VACTERL association without the "V and L".

Authors:  S Padma; P Shanmuga Sundaram; Bhavya Sonik
Journal:  Indian J Nucl Med       Date:  2014-01

Review 3.  Aspiration Risk and Respiratory Complications in Patients with Esophageal Atresia.

Authors:  Thomas Kovesi
Journal:  Front Pediatr       Date:  2017-04-03       Impact factor: 3.418

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.